All Posts By

Smartkarma Daily Briefs

Daily Brief Energy/Materials: Indika Energy and more

By | Daily Briefs, Energy & Materials Sector

In today’s briefing:

  • Morning Views Asia: Indika Energy


Morning Views Asia: Indika Energy

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief TMT/Internet: Samsung Electronics, Intouch Holdings, ARM Holdings, NVIDIA Corp, Western Digital, iQIYI Inc, Micron Technology, Monolithic Power Systems, Inc, Bitcoin and more

By | Daily Briefs, TMT/Internet

In today’s briefing:

  • Is Samsung M&A About to Happen?
  • StubWorld: Intouch “Cheap” As Thaksin Returns
  • ARM Holdings Pre-IPO – Pre-Privatisation to Pre-Listing Changes – Slower Growth, Lower Margins
  • ARM Holdings IPO: The Bull Case
  • Nvidia: Better than Dreamed
  • Western Digital Corporation: How Cloud is Redefining Their Revenue Streams! – Major Drivers
  • [iQIYI, Lnc. (IQ US, BUY, TP US$6.25) Review]: Ads Revenue Will Continue to Have Fair Growth
  • Memory Monitor: SK Hynix Appearing Prescient; Relative Value in Micron
  • Monolithic Power Systems Inc.: An Exciting Leap into EV & AI Domains! – Major Drivers
  • Comparing Liquidity on Uniswap and Binance


Is Samsung M&A About to Happen?

By Ken S. Kim

  • Local press states that Samsung Electronics Pref Shares (005935 KS)sold shares as they look to invest in their future capex
  • The capex amount for 2023 will be around 40-50 trillion KRW and it doesn’t seem like W3 trillion is a needle mover
  • With a new 3 year shareholder return plan, I would think maybe cash is needed to secure ammunition for M&A

StubWorld: Intouch “Cheap” As Thaksin Returns

By David Blennerhassett

  • Intouch Holdings (INTUCH TB) plumbs new 12-month lows for its implied stub, and NAV discount as the former PM returns from exile. 
  • Preceding my comments on Intouch are the current setup/unwind tables for Asia-Pacific Holdcos.
  • These relationships trade with a minimum liquidity of US$1mn, and a % market capitalisation >20%.

ARM Holdings Pre-IPO – Pre-Privatisation to Pre-Listing Changes – Slower Growth, Lower Margins

By Sumeet Singh

  • Softbank Group (9984 JP) aims to raise around US$8-10bn via selling some of its stake in ARM Holdings’ US IPO.
  • ARM develops and licences high-performance, low-cost, and energy-efficient CPU products and related technology, which is used by semiconductor companies and OEMs to develop their own products.
  • In this note, we compare its recent performance versus its performance prior to its privatisation and discuss the changes since then.

ARM Holdings IPO: The Bull Case

By Arun George

  • ARM Holdings (1822695D US) is the world’s most widely licensed and deployed processor. Softbank Group (9984 JP) is seeking to raise about US$6-10 billion by listing ARM on Nasdaq.   
  • Softbank Privatised ARM for US$32bn in 2016 and unsuccessfully tried to sell it to NVIDIA Corp (NVDA US) for US$40bn in 2022. In August, Softbank acquired Vision Fund’s ARM stake.
  • The bull case rests on the growth in licensees, high customer switching costs, rising royalty rates, strong revenue visibility and a highly profitable and cash-generative business model.

Nvidia: Better than Dreamed

By Douglas O’Laughlin

  • Nvidia, in characteristic fashion, murdered EPS estimates.
  • Revenue was $2 billion ahead of the guide, and the guide was another $4 billion ahead of consensus for the next quarter.
  • Going into the print, many people were concerned that positioning was bad, i.e., everyone was bullish and expectations were too high. Well, they did not disappoint.

Western Digital Corporation: How Cloud is Redefining Their Revenue Streams! – Major Drivers

By Baptista Research

  • Western Digital Corporation delivered an all-around beat in the quarter, with total revenue of $2.7 billion.
  • In the fourth quarter, cloud comprised 37% of all revenue at $1 billion, down 18% from the previous quarter and 53% from the previous year.
  • Shipments of nearline bits were 59 exabytes, a 26% sequential decline driven by persistent difficulties among cloud clients.

[iQIYI, Lnc. (IQ US, BUY, TP US$6.25) Review]: Ads Revenue Will Continue to Have Fair Growth

By Shawn Yang

  • IQ reported 2Q23 revenue and non-GAAP net income 0.2%/28.5% vs cons.
  • We cut our projections for 3Q23’s membership services revenue, but increased estimations for online ads services revenue, and raised margin forecasts for 2023.  
  • We maintain our US$ 6.25 TP, implying 16.2X PE in 2023.

Memory Monitor: SK Hynix Appearing Prescient; Relative Value in Micron

By Vincent Fernando, CFA

  • Major memory names have fallen with the recent market concerns and only staged a small reboound due to Nvidia’s bullish results.
  • NAND and DRAM price declines have stabilized. Demand for DRAM from servers is expected to exceed that from mobile devices, driven by AI usage.
  • We see relative value in Micron vs. Nanya Technology and SK Hynix. SK Hynix is ahead of the game for AI, and Nanya offers focused DRAM exposure however.

Monolithic Power Systems Inc.: An Exciting Leap into EV & AI Domains! – Major Drivers

By Baptista Research

  • Monolithic Power Systems managed to exceed the revenue expectations as well as the earnings expectations of Wall Street.
  • Storage and computing revenue increased in the quarter.
  • Industrial revenue for the second quarter of 2023 also increased due to higher equipment sales for power sources and industrial meter applications.

Comparing Liquidity on Uniswap and Binance

By Kaiko

  • Market depth is a widely used measure of liquidity, commonly calculated across the order books of cryptocurrency pairs on centralized exchanges (CEXes).
  • It provides the amount of bids and asks at varying distances from the mid-price, encompassing a range from -0.1% to 10%.
  • This chart shows cumulative ETH-USDT bid and ask volumes at various levels on the ten largest CEXes.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Consumer: Meituan, CD Projekt, UMW Holdings, Boustead Plantations, Cello World Limited, Vipshop Holdings, Tokyo Stock Exchange Tokyo Price Index Topix, Polaris Holdings, Telenet Group Holding NV and more

By | Consumer, Daily Briefs

In today’s briefing:

  • MT (Meituan 3690 HK): 2Q23, Record High Op Profit, 38% Buy
  • Quiddity Leaderboard SE600 Sep 23: 6 ADDs/DELs As Things Stand; More Possible
  • UMW Holdings (UMWH MK): Sime Darby’s Pre-Conditional MGO
  • Boustead Plantations (BPLANT MK): Pre-Conditional MGO at RM1.55
  • Cello World Pre-IPO Tearsheet
  • Sime Darby/UMW: It’s All About Scale
  • VIPShop (VIPS US): Attractive Value Play Underappreciated by Investors Looking for Growth
  • Companies Should Show a Path to Accelerated Profit Growth Rather than Shareholder Returns
  • Polaris Holdings (3010) – Positioned to Leverage Demand Recovery
  • Liberty/​​Telenet: Re-Opening of Tender Offer


MT (Meituan 3690 HK): 2Q23, Record High Op Profit, 38% Buy

By Ming Lu

  • Total revenue grew by 33% YoY, which is the highest growth rate in the past seven quarters.
  • The company achieved a higher operating profit in 2Q23 after turned the profit positive in 1Q23.
  • The stock price has risen by 20% since our last buy rating, but we believe there will be still 38% upside for yearend 2024.

Quiddity Leaderboard SE600 Sep 23: 6 ADDs/DELs As Things Stand; More Possible

By Janaghan Jeyakumar, CFA

  • In this insight, we take a look at the names leading the race to become ADDs/DELETEs for the SE600 and EURSTX Indices for the September 2023 Rebalance.
  • I currently expect 6 ADDs and 6 DELETEs for the SE600 index in the September 2023 rebalance but these rankings could change prior to the base date.
  • After the September 2023 rebalance, SimCorp A/S (SIM DC) could get deleted from the SE600 index and trigger an intra-review index change.

UMW Holdings (UMWH MK): Sime Darby’s Pre-Conditional MGO

By Arun George

  • Sime Darby (SIME MK) entered a conditional sale and purchase agreement (SPA) to acquire PNB’s 61.18% stake in UMW Holdings (UMWH MK) for RM5.00 per share.
  • Once the SPA becomes unconditional, Sime Darby must launch an MGO for the remaining UMW shares at RM5.00 per share, an 8.2% premium to the last close.  
  • The SPA is conditional on Sime Darby’s shareholder approval. The SPA and MGO are targeted to be completed in 4Q23 and 1Q24, respectively.

Boustead Plantations (BPLANT MK): Pre-Conditional MGO at RM1.55

By Arun George

  • Kuala Lumpur Kepong (KLK MK) will acquire 33.00% of Boustead Plantations (BPLANT MK)‘s outstanding shares from Boustead Holdings/BHB at RM1.55 per share. The purchase is conditional on BHB shareholder approval.
  • Once the purchase becomes unconditional, the joint offerors (KLK, BHB, LTAT) will be required to launch an MGO at RM1.55 per share, a 13.1% premium to the last close. 
  • The MGO will have no minimum acceptance condition. The offer is attractive and represents an all-time high. The MGO is expected to be complete in 4Q23.

Cello World Pre-IPO Tearsheet

By Clarence Chu

  • Cello World Limited (CW IN) is looking to raise around US$210m in its upcoming India IPO. The bookrunners on the deal are Kotak, JM Financial, ICICI, IIFL, and Motilal Oswal.
  • Cello World (CW) is an Indian consumer products company. The firm is a leading company in the consumerware market in India.
  • According to the Technopak Report, the firm’s consumer houseware, writing instruments and stationery, and moulded furniture and allied products categories are amongst the largest brands in the Indian consumerware market.

Sime Darby/UMW: It’s All About Scale

By David Blennerhassett

  • In one of the largest M&A transactions in Malaysia, Sime Darby (SIME MK) intends to acquire a 61.2% stake in UMW Holdings (UMWH MK) from Permodalan Nasional Bhd for RM3.57bn. 
  • Sime Darby is paying RM5/share, a token 9.9% premium to last close, but more like 25% when factoring in apparent news leakage.
  • Once the stake sale is completed, Sime Darby will launch an unconditional MGO for all remaining shares not held. This transaction is expected to be wrapped up in early 2024.

VIPShop (VIPS US): Attractive Value Play Underappreciated by Investors Looking for Growth

By Eric Chen

  • Over the last decade, VIPShop proved it is the undisputed leader in China’s online discount retail business with the longest streak of profitability and impressive ROE among China internet names.
  • Investors are misplaced to look to the stock for growth. Rather, it is cash cow in mature business with deep moat and run by disciplined management who cares about shareholders.
  • Trading at 4.5x our FY23 earnings excluding net cash, it valuation is attractive even compared to depressed sector comps. Expect 20% CAGR of return by 2025 driven by intrinsic value.

Companies Should Show a Path to Accelerated Profit Growth Rather than Shareholder Returns

By Aki Matsumoto

  • Metrical’s past analysis also shows that a company’s capital allocation to investors is effective in raising valuations, so a proper allocation between investment and shareholder return is a baseline.
  • The correlation analysis between TOPIX and nominal GDP suggests that the shift from deflation to inflation has triggered overseas investors to focus on the further expansion of company profits.
  • While average P/B and ROE have remained flat, the rise in P/E has boosted the stock recently. This suggests that further share price appreciation will require an increase in profits.

Polaris Holdings (3010) – Positioned to Leverage Demand Recovery

By Astris Advisory Japan

  • Positioned for a major resurgence in demand – Q1 FY3/2024 results were a culmination of efforts made by management to improve the profit structure of Polaris’ business model, a successful recapitalization strategy, and a recovery in the hotel industry.
  • Demand was normalizing to pre-pandemic levels for Polaris’ domestic and overseas operations, with the business generating a quarterly operating margin of 6.6%, the highest since Q1 FY3/2017.
  • Newly disclosed KPIs highlight robust activity in the domestic market, with Q1 FY3/2024 domestic RevPAR rising 84.9% YoY. 

Liberty/​​Telenet: Re-Opening of Tender Offer

By Jesus Rodriguez Aguilar

  • Liberty has waived the 95% threshold condition. Liberty has now mandatorily opened again the tender given it owns more than 90% (93.43%),  on same terms until 13 September (settlement 27 September).
  • At 5.9x EV/Fwd EBITDA (vs. 5.4x EV/20e EBITDA for Orange Belgium minorities), the offer is relatively cheap, but also reflects the uncertainties surrounding Citymesh’s entrance and risk of market share losses.
  • Spread is positive. After the second acceptance period closes, I believe the delisting is extremely likely. With limited liquidity and floor dividend no longer guaranteed, recommendation is accept the offer. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Financials: Road King Infrastructure, China UnionPay, Deutsche Beteiligungs AG and more

By | Daily Briefs, Financials

In today’s briefing:

  • Road King – Earnings Flash – H1 FY 2023 Results – Lucror Analytics
  • China UnionPay More Than Triples Registered Capital to $1.37 Billion
  • Deutsche Beteiligungs – On track to meet the FY23 guidance


Road King – Earnings Flash – H1 FY 2023 Results – Lucror Analytics

By Leonard Law, CFA

Road King’s H1/23 results were mixed in our view. The company reported robust top-line growth, albeit gross profit plunged due to lower ASP of properties delivered. In addition, cash dividends from toll roads declined materially, owing to the non-renewal of the Tangjin expressway concession upon expiry in April.

Positively, Road King’s net debt continued to decrease, as it repaid borrowings using cash collection from property deliveries. The company could sustain its sales momentum in H2/23, as it is poised to launch the So Kwun Wat project (its sole remaining undeveloped project in Hong Kong) for sale.

We believe Road King will remain current on its obligations for the next 12 months. That said, the company’s medium-term prospects appear dim. Moreover, the small and dwindling land bank might suffice for only another two years of development. In the meantime, the company is likely to continue repurchasing offshore bonds.

We move our LARA to “High Risk”. We maintain our “Hold” recommendation on the ROADKG 2024 notes, but move to “Not Recommended” on the remaining notes.


China UnionPay More Than Triples Registered Capital to $1.37 Billion

By Caixin Global

  • Regulators cleared state-backed bank card giant China UnionPay, the world’s largest provider of debit cards, to more than triple its registered capital to almost 10 billion yuan ($1.37 billion).
  • Such a capital increase usually is intended to improve a payment institution’s risk control system and ensure the safety and stability of the business, a senior analyst in the payment industry said.
  • People at UnionPay told Caixin that the capital increase was a distribution of unrealized shareholder equity and was a normal financial adjustment with no impact on its shareholding structure.

Deutsche Beteiligungs – On track to meet the FY23 guidance

By Edison Investment Research

Deutsche Beteiligungs (DBAG) posted a 20% NAV total return in the nine months to end-June 2023, thereby recouping the valuation loss in FY22. The uplift to last carrying value from its recently agreed sale of R+S (implying a healthy internal rate of return of over 40%) contributed €14m to its net income in Q323. As a result, management now expects FY23 results to be at the upper half of its guidance of net income at €85–115m and NAV of €610–715m. DBAG’s asset management business delivered a profit of €11.3m in 9M23, on track to meet management’s FY23 guidance of €13–15m. DBAG’s shares currently trade at a c 15% discount to last reported NAV (with the latter not capturing the value of the asset management business).


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: Wuxi Biologics, Mirxes Holding, Pfizer Inc, Quality Systems, Vertex Pharmaceuticals and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Wuxi Biologics (2269 HK): Mixed 1H23 Result; Strong Non-COVID Business Momentum Enhances Visibility
  • Mirxes Pre-IPO: Early Signs of Commercialization Challenges
  • Pfizer Inc: Delving into Their Game Plan For Future Growth! – Major Drivers
  • NextGen Healthcare: What Is The Value That The Company Can Get From A Potential Sale?
  • Vertex Pharmaceuticals: Exploring the Pipeline: From Pain Relief to Sickle Cell Miracles! – Major Drivers


Wuxi Biologics (2269 HK): Mixed 1H23 Result; Strong Non-COVID Business Momentum Enhances Visibility

By Tina Banerjee

  • Wuxi Biologics (2269 HK) recorded 8% YoY revenue growth to RMB8.5B in 1H23. Strong momentum continued in the base business, with the non-COVID revenue achieving a 60% YoY growth.  
  • Ramping up of new manufacturing facilities, maintenance shutdown of existing facilities, slowdown in funding environment in China, and increasing expenses have negatively impacted the profitability.
  • Total number of integrated projects reached a new record of 621 with 46 integrated projects added to the pipeline. As of June 30, backlog increased 9% YoY to $20.1B.

Mirxes Pre-IPO: Early Signs of Commercialization Challenges

By Ke Yan, CFA, FRM

  • Mirxes, a Singapore-headquartered RNA technology company with a focus on cancer screening, plans to raise up to US$100m via a Hong Kong listing.
  • In this insight, we examine its key product, GASTROClear’s technical and clinical data. We also look at the competitive landscape.
  • We are of the view that the company’s product, despite improving the accuracy over incumbent competitors marginally, is not a killer product and will face challenges in ramping up sales.

Pfizer Inc: Delving into Their Game Plan For Future Growth! – Major Drivers

By Baptista Research

  • Pfizer managed to surpass the revenue and earnings expectations of analysts.
  • Operationally, non-COVID-19 revenue increased, but total revenue decreased in the quarter.
  • The projected revenue declines in both PAXLOVID and COMIRNATY principally brought on this loss.

NextGen Healthcare: What Is The Value That The Company Can Get From A Potential Sale?

By Baptista Research

  • This is a special one-time report on NextGen Healthcare (NASDAQ:NXGN) given the prevailing reports of the company exploring a sale.
  • Amidst prevailing economic uncertainties, the healthcare sector is shining brightly as a hub of merger and acquisition (M&A) activities.
  • NextGen Healthcare is at the heart of these discussions, given the recent flurry in its stock price, propelled by whispers of potential strategic shifts, including a possible sale.

Vertex Pharmaceuticals: Exploring the Pipeline: From Pain Relief to Sickle Cell Miracles! – Major Drivers

By Baptista Research

  • Vertex Pharmaceuticals delivered a solid result and managed an all-around beat last quarter.
  • The company’s continued momentum in all aspects, particularly in the Cystic Fibrosis (CF) business, has led to solid growth in global product revenue.
  • Vertex has strategically invested in promising therapies for severe sickle cell disease, transfusion-dependent beta-thalassemia, acute pain relief, and CF treatments.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Most Read: Taiwan Semiconductor (TSMC) – ADR, Alibaba (ADR), Hanwha Ocean, M&A Research Institute, Shibaura Mechatronics, Doosan Robotics, Eoflow , Samsung Electronics, Intouch Holdings and more

By | Daily Briefs, Most Read

In today’s briefing:

  • Taiwan Tech Weekly: Key Supply Chain Names to Watch for Nvidia’s Earnings Today
  • Alibaba: Navigating in Reverse
  • Korea – Positioning in Ecopro, JYP Entertainment, Hanwha Ocean, Hanmi Semi, CJ Corp, E-Mart
  • M&A Research Institute Holdings (9552) TOPIX Inclusion
  • Shibaura Mechatronics (6590) Secondary Offering & Buyback
  • Doosan Robotics IPO Preview
  • EOFLOW/Medtronic Tender: Irrational Exuberance
  • Hanwha Ocean: Big Shares Dilution from Rights Offering of 2 Trillion Won
  • Is Samsung M&A About to Happen?
  • StubWorld: Intouch “Cheap” As Thaksin Returns


Taiwan Tech Weekly: Key Supply Chain Names to Watch for Nvidia’s Earnings Today

By Vincent Fernando, CFA

  • Nvidia will report its earnings today U.S.-time, we outline the key Taiwan AI supply chain names to watch around the earnings.
  • TSMC has maintained its full-year revenue guidance despite media reports questioning whether a further downgrade was coming.
  • Hon Hai produces over 50% of Nvidia’s AI hardware according to media reports.

Alibaba: Navigating in Reverse

By Oshadhi Kumarasiri

  • Alibaba (ADR) (BABA US)‘s New Retail strategy stumbled, prompting the company to revert to its e-commerce origins with a renewed emphasis on social commerce.
  • Creating a social media platform could be relatively simple, yet turning it into a prosperous venture amid established social media giants could be challenging.
  • Branching out from social media to e-commerce might be straightforward, but Alibaba Group Holding (9988 HK)‘s unprecedented reverse path could present unique challenges.

Korea – Positioning in Ecopro, JYP Entertainment, Hanwha Ocean, Hanmi Semi, CJ Corp, E-Mart

By Brian Freitas


M&A Research Institute Holdings (9552) TOPIX Inclusion

By Travis Lundy

  • Yesterday, M&A Research Institute (9552 JP) announced it would list on the TSE Prime section on 29 August, which means it will join TOPIX at the close of 28-Sep-2023.
  • This is NOT a surprise. On 27 June, the company announced a secondary offering of 1.631mm shares (by the founder/CEO), and said it had applied for TSE Prime transfer. 
  • I take a look at how this could play out. 

Shibaura Mechatronics (6590) Secondary Offering & Buyback

By Travis Lundy


Doosan Robotics IPO Preview

By Douglas Kim

  • Doosan Robotics is getting ready to complete its IPO in Korea in September. The expected IPO price range is 21,000 won to 26,000 won.
  • The company estimates its sales to surge from 67 billion won in 2023 to 766.3 billion won in 2027, representing 83.9% CAGR from 2023 to 2027.
  • One of the major reasons why local investors will have a positive view of Doosan Robotics is due to Samsung’s investment in Rainbow Robotics whose share price increased 232% YTD. 

EOFLOW/Medtronic Tender: Irrational Exuberance

By Arun George

  • Eoflow (294090 KS) shares were up 4.4% on the back of Medtronic Plc (MDT US)’s earnings call comment that it expects the acquisition to close at the end of 2023.
  • The bear view is that Medtronic’s messaging remained unchanged as it is still assessing Insulet Corp (PODD US) lawsuit and the potential impact on the timing and/or pricing.
  • The bull view is that Medtronic’s comment underscores its commitment to close the transaction. It’s tough to take a call on risk/reward profile – at best it’s a brave buy. 

Hanwha Ocean: Big Shares Dilution from Rights Offering of 2 Trillion Won

By Douglas Kim

  • After the market close on 23 August, Hanwha Ocean (042660 KS) confirmed that it will conduct a massive rights offering of 2 trillion won.
  • The expected rights offering price is 22,350 won, which is 36% discount to current price. 
  • We believe this rights offering is likely to dilute the existing shareholders and negatively impact Hanwha Ocean’s share price.

Is Samsung M&A About to Happen?

By Ken S. Kim

  • Local press states that Samsung Electronics Pref Shares (005935 KS)sold shares as they look to invest in their future capex
  • The capex amount for 2023 will be around 40-50 trillion KRW and it doesn’t seem like W3 trillion is a needle mover
  • With a new 3 year shareholder return plan, I would think maybe cash is needed to secure ammunition for M&A

StubWorld: Intouch “Cheap” As Thaksin Returns

By David Blennerhassett

  • Intouch Holdings (INTUCH TB) plumbs new 12-month lows for its implied stub, and NAV discount as the former PM returns from exile. 
  • Preceding my comments on Intouch are the current setup/unwind tables for Asia-Pacific Holdcos.
  • These relationships trade with a minimum liquidity of US$1mn, and a % market capitalisation >20%.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars



Daily Brief Thailand: Bangkok Dusit Medical Services and more

By | Daily Briefs, Thailand

In today’s briefing:

  • Bangkok Dusit Medical Services (BDMS TB): International Patients Drove 2Q23 Performance


Bangkok Dusit Medical Services (BDMS TB): International Patients Drove 2Q23 Performance

By Tina Banerjee

  • Bangkok Dusit Medical Services (BDMS TB) recorded 10% YoY growth in revenue from hospital operations in 2Q23, driven by 22% YoY from international patients, which contributed 26% of revenue.
  • Thai patient revenues increased 7% YoY, despite COVID-19 related revenue decreased sharply from year-ago quarter.
  • EBITDA margin declined 70 basis points YoY to 22.6% due to lower occupancy rate and economies of scales from a decline in number of COVID-19 patients.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Australia: APA Group, 3P Learning, Recce Ltd and more

By | Australia, Daily Briefs

In today’s briefing:

  • APA Group Placement – Well Flagged Deal, but Lacks in Accretion
  • 3P Learning (3PL): Steady Through the 3Rs, Eyes on FY24
  • Recce Pharmaceuticals – R327 progressing in rapid infusion study


APA Group Placement – Well Flagged Deal, but Lacks in Accretion

By Clarence Chu

  • APA Group (APA AU) is looking to raise A$675m (US$430m) in its primary follow-on to partially fund its acquisition of the Alinta Energy assets in the Pilbara region.
  • The deal is a well flagged one with APA having been one of the last remaining bidders on the asset. Short interest has been on the rise as well.
  • However, the deal doesn’t seem accretive at our end, and the results reported today seemed to have missed analyst expectations.

3P Learning (3PL): Steady Through the 3Rs, Eyes on FY24

By Anik Siwach

  • Holistic Educational Suite: 3PL enriched its product portfolio, with the APAC debut of WritingLegends and BrightPath Assessement. 
  • Steady Financial Growth: Amidst challenges in the UK, 3PL’s 9% ARPU growth highlights its consistent performance and market strength. 
  • Setting the Pace: With attractive-priced offerings, an integrated product approach, and an innovative teacher training vision, 3PL is expected to continue growing its top line as more schools join. 

Recce Pharmaceuticals – R327 progressing in rapid infusion study

By Edison Investment Research

Recce recently reported the completion of its data review from its earlier long-infusion Phase I study of the intravenous (IV) RECCE 327 (R327) formulation, confirming that the drug candidate shows favourable safety characteristics, a robust dose-dependent pharmacokinetic drug concentration response, as well as evidence of increased drug concentration into the urinary tract. The company is proceeding with a Phase I/II study assessing using a more rapid infusion rate, with recent completion of the first 2,500mg cohort of the Phase I part ahead of schedule. Obtaining financing is a near-term strategic priority given the cash at hand (A$1.6m at 30 June 2023), and the company’s current cash runway is short (into late Q3 CY23). Recce has signalled that it is seeking to raise A$12–15m. After rolling forward our estimates and updating forex assumptions, we obtain an rNPV valuation of A$562.4m (or A$3.15 per share), up from A$535.6m previously.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief South Korea: Eoflow , Hanwha Ocean, Doosan Robotics and more

By | Daily Briefs, South Korea

In today’s briefing:

  • EOFlow/Medtronic: What Lawsuit?
  • Korea – Positioning in Ecopro, JYP Entertainment, Hanwha Ocean, Hanmi Semi, CJ Corp, E-Mart
  • EOFLOW/Medtronic Tender: Irrational Exuberance
  • Doosan Robotics IPO Preview


EOFlow/Medtronic: What Lawsuit?

By David Blennerhassett

  • On the 8th of August, Insulet Corp (PODD US) filed a lawsuit accusing Eoflow (294090 KS) of the misappropriation of trade secrets, patent infringement, and trademark dilution.
  • The filing was pretty heavy on accusations. EOFlow declined ~11% on the news.
  • Undeterred, Medtronic (MDT US) continues to preach all is peachy, suggesting the EOFlow merger is a go, and Medtronic will deal with the lawsuit, as and when.

Korea – Positioning in Ecopro, JYP Entertainment, Hanwha Ocean, Hanmi Semi, CJ Corp, E-Mart

By Brian Freitas


EOFLOW/Medtronic Tender: Irrational Exuberance

By Arun George

  • Eoflow (294090 KS) shares were up 4.4% on the back of Medtronic Plc (MDT US)’s earnings call comment that it expects the acquisition to close at the end of 2023.
  • The bear view is that Medtronic’s messaging remained unchanged as it is still assessing Insulet Corp (PODD US) lawsuit and the potential impact on the timing and/or pricing.
  • The bull view is that Medtronic’s comment underscores its commitment to close the transaction. It’s tough to take a call on risk/reward profile – at best it’s a brave buy. 

Doosan Robotics IPO Preview

By Douglas Kim

  • Doosan Robotics is getting ready to complete its IPO in Korea in September. The expected IPO price range is 21,000 won to 26,000 won.
  • The company estimates its sales to surge from 67 billion won in 2023 to 766.3 billion won in 2027, representing 83.9% CAGR from 2023 to 2027.
  • One of the major reasons why local investors will have a positive view of Doosan Robotics is due to Samsung’s investment in Rainbow Robotics whose share price increased 232% YTD. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Singapore: OUE Commercial REIT and more

By | Daily Briefs, Singapore

In today’s briefing:

  • kopi-C with OUE Commercial REIT’s CEO: “Diversity is our strength”
  • kopi-C with OUE C-REIT’s CEO: “Diversity is our strength”


kopi-C with OUE Commercial REIT’s CEO: “Diversity is our strength”

By Geoff Howie

  • kopi-C with OUE C-REIT’s CEO: “Diversity is our strength” OUE Commercial REIT’s CEO Han Khim Siew believes that team diversity is essential to delivering on the REIT’s targets.
  • OUE C-REIT invests in income-producing real estate used primarily for commercial purposes (including real estate used primarily for office and/or retail purposes) in financial and business hubs, and/or hospitality and/or hospitality-related purposes, as well as real estate-related assets.

kopi-C with OUE C-REIT’s CEO: “Diversity is our strength”

By Geoff Howie

  • kopi-C with OUE C-REIT’s CEO: “Diversity is our strength” OUE Commercial REIT’s CEO Han Khim Siew believes that team diversity is essential to delivering on the REIT’s targets.
  • OUE C-REIT invests in income-producing real estate used primarily for commercial purposes (including real estate used primarily for office and/or retail purposes) in financial and business hubs, and/or hospitality and/or hospitality-related purposes, as well as real estate-related assets.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars